CAJ | 학술논문

目的：探讨参附注射液联合黄芪精口服液干预心力衰竭的疗效及血清内皮素（ET）、前脑利尿肽（BNP）、左室射血分数（LVEF）水平。方法：37例心力衰竭患者随机分为干预组19例与对照组18例，对照组采取西医常规对症治疗，干预组在对照组基础上加用参附注射液联合黄芪精口服液，观察两组ET、BNP、LVEF及疗效。结果：干预组不良事件发生率显著低于对照组（P<0.05），其疗效积分、住院天数均优于对照组（P<0.05）；治疗后两组患者ET、LVEF均显著优于治疗前（P<0.05），且干预组优于对照组（P<0.05）。结论：参附注射液联合黄芪精口服液干预心力衰竭有利于提高疗效和减少不良事件、减少住院天数但并没有增加住院费用，值得进一步扩大研究范围和病例数量、规模去深入研究，以得到更有力的数据指导临床治疗。
목적：탐토삼부주사액연합황기정구복액간예심력쇠갈적료효급혈청내피소（ET）、전뇌이뇨태（BNP）、좌실사혈분수（LVEF）수평。방법：37례심력쇠갈환자수궤분위간예조19례여대조조18례，대조조채취서의상규대증치료，간예조재대조조기출상가용삼부주사액연합황기정구복액，관찰량조ET、BNP、LVEF급료효。결과：간예조불량사건발생솔현저저우대조조（P<0.05），기료효적분、주원천수균우우대조조（P<0.05）；치료후량조환자ET、LVEF균현저우우치료전（P<0.05），차간예조우우대조조（P<0.05）。결론：삼부주사액연합황기정구복액간예심력쇠갈유리우제고료효화감소불량사건、감소주원천수단병몰유증가주원비용，치득진일보확대연구범위화병례수량、규모거심입연구，이득도경유력적수거지도림상치료。
Objective:To investigate the efficacy of intervening congestive heart failure by Shenfu injection combined with astragalus membrana-ceous and their influence on levels of serum endothelin (ET), brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF). Methods:37 cases of patients with congestive heart failure were randomly divided into intervention group (19 cases) and control group (18 cases), the control group treated by conventional western medicine treatment, while intervention group by Shenfu injection combined with astragalus membranaceous on the basis of treatment of control group, and observed the ET, BNP, LVEF and efficacy of two groups. Results:The occurrence of adverse events of intervention group was significantly lower than that of control group (P<0.05), and its efficacy scores and hospitalization days were all better than those of control group (P<0.05);after treatment, the levels of ET and LVEF of two groups were both significantly better than those of before treat-ment (P<0.05), and those of intervention group were better than control group (P<0.05). Conclusion:Intervening congestive heart failure by Shenfu injection combined with astragalus membranaceous, which is helpful to improve efficacy and reduce adverse events and hospitalization days without expenses increased, deserves to intensive study by further expanding research scope, number and scale of cases, in order to get more powerful data which can guide clinical treatment.